Harvest One Cannabis Stock (TSXV: HVT) (OTC: HRVOF) - Investor Dashboard


➔ Harvest One Cannabis
TSX Venture Exchange: HVT
OTC Ticker: HRVOF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  26
Established: 2015
CEO: Andreas Gedeon

Summary

Fiscal Year-End: June
Facilities: 1
Dried Flower: Production and Sale
Extracts:   none
Number of Patients: na
Headquarters: Vancouver, BC

Financials (03/31/18)

Cash on hand: $79.5mm
Fixed Investment: $9.5mm
Shareholders’ Equity: $93.3mm
Revenues – Last Quarter: $33K
Adj. Gross Margin : 2.8%
EPS : -$0.02

Capital Structure (05/29/18)

Last Financing:  22.11mm Units at $1.82
Basic Shares: 173.4mm
Warrants: 33.8mm
Options: 7.7mm
Diluted Shares 214.9mm

Company Brief

Harvest One is a holding company that owns Canadian ACMPR licensed producer United Greeneries, Swiss medical cannabis brand Satipharm, and sleep aid companies Dream Water and Dream Water Canada. United Greeneries received its cultivation license in June 2016. The company has facilities in Lucky Lake, Saskatchewan and Duncan, British Columbia, as well as an Aldergrove, British Columbia facility expected to begin construction in August 2018. Satipharm, which is generating revenue, focuses on oral delivery technologies. It has been producing Gelpell ® Microgel Capsules, a pharmaceutical grade product with GMP production, since May 2015. The company is focused on growth and distribution in the EU and Australia. Satipharm plans to export Gelpell ® Microgel products into the Canadian ACMPR market.

Featured Video

The United Greeneries’ flagship facility on Vancouver Island in Canada.


Harvest One completes acquisition of Dream Water and Dream Water Canada

The transaction will deliver a ready-made consumer goods marketing, distribution and product development division to Harvest One.  Dream Water is a natural, 2.5oz, 0-calorie, liquid sleep shot. Along with its sleep powder, Dream Water helps promote relaxation and support restful sleep. Dream Water is sold online and in over 30,000 North American retail outlets, while currently generating approximately $6 million per annum in revenue from its current product lines.

Dream Water has been embraced by a wide variety of celebrities including Kate Perry, Demi Moore, Paris Hilton, Kendall Jenner and more. It has also been featured in many mainstream media outlets. Dream Water was voted Canada’s Product of the Year for the Wellness Innovation category in 2017 and was awarded ‘Best in Show’ by Chatelaine.


HVST shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector

united-greeneries-satipharm-HVST

United Greeneries is a Canadian ACMPR Licensed Producer and will be HVST’s horticultural arm and recreational brand.

  • ACMPR (MMPR) Licensed Producer Duncan Facility in BC
  • Current capacity of ~1,000 kg/year
  • Aldergrove, BC facility targets 8,000 kg/year
  • Lucky Lake Facility in SK targets 12,000 kg/year
  • Outdoor grow in BC targets 50,000 kg/year with regulatory changes

Satipharm is specialized in the development and manufacturing of cannabis- based health products and will be the company’s medical and health brand

  • Flagship Gelpell ® Microgel Capsules to lead growth
    • Near-term growth from supplement sales in EU
    • Mid-term growth from entry into regulated markets (Canada, Australia, etc.)
    • Significant growth opportunities globally
  • Global exclusive rights to Gelpell ® on cannabis applications; Gelpell Phase 1
  • Growing portfolio of delivery technology IP

Meet the CEO

A brief Q&A with Harvest One CEO Andreas Gedeon

Focused on recreational and medical markets
HVST will be a well-financed, growth- oriented cannabis company focused on supplying Canadian and international medical and recreational cannabis markets through two distinct operating brands:

United Greeneries
Canadian ACMPR Licensed Producer with focus on large-scale horticultural operations for the upcoming Canadian recreational cannabis market

Satipharm
International medical cannabis brand with focus on oral delivery technologies for strategic entry in emerging medical cannabis markets and the existing medical cannabis market in Canada


Highlights

  • Recreational and medical focus
  • Three brands
    • United Greeneries focused on large-scale production
    • Satipharm focused on oral delivery technologies
    • Dream Water and Dream Water Canada focused on the sleep aid market
  • Serving Canada and international markets
  • $62 million cash position

Growth Strategy

  • Build 59,000-square-foot Aldergrove, BC facility with 8,000 kg/year capacity
  • In the final stages of the Lucky Lake Facility ACMPR application process
  • With regulatory changes, use 398 acres in BC for outdoor grow
  • Expand Satipharm distribution in the EU, Australia, and preparing to import into Canada
  • Enter the global sleep and cannabis markets through Dream Water

Differentiators

  • Three indoor production facilities in two provinces
  • Wholesale rather than investing in competitive medical distribution in Canada
  • In-house QA/QC laboratory
  • Technology-driven portfolio of health products
  • Active in European CBD markets and engaged in clinical trials
  • Site selected for potential outdoor grow

Institutional Analyst Coverage


Curated Stories & News


Visit Harvest One Cannabis, Inc.
at www.harvestone.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Harvest One Cannabis, Inc., is a client of NCV Media, LLC. Read our full disclaimer.